This 1994 article from The Sacramento Bee details the advocacy of Leslie Gazeley, who became a dedicated activist following the death of her newborn son, Jordan, due to a Group B streptococcus (GBS) infection. After losing Jordan only seven hours after an emergency delivery, Gazeley discovered that GBS is a leading cause of life-threatening infections in newborns, yet she had never been informed of the risks. Her tragedy spurred a national campaign to ensure other parents were educated and offered testing, eventually leading to the introduction of California Assembly Bill 3081.

Key Facts & Advocacy Impact

• The Loss of Jordan: Jordan Gazeley died in October 1991, just seven hours after birth, without his parents present to say goodbye.

• Understanding GBS: Group B strep is a naturally occurring bacteria found in up to 35% of women. While different from "strep throat," it is the primary cause of newborn infection and can lead to permanent physical or mental disabilities.

• Statistical Toll: At the time of publication, approximately 12,000 infants were infected annually in the U.S., with over 200 deaths occurring each year in California alone.

• Preventability: Activists highlighted that a reliable $35 test and existing treatment methods could prevent these tragedies.

• Legislative Efforts: As the national public relations coordinator for the Group B Strep Association, Gazeley lobbied for AB 3081.

• The Goal of AB 3081: The bill aimed to require doctors to inform pregnant women about GBS and provide the option for testing, allowing patients to decide for themselves.

This 1994 bill analysis details the legislative trajectory of Assembly Bill 3081, authored by Assemblywoman Barbara Lee. The bill was designed to address the prevention of neonatal Group B streptococcal (GBS) infection through standardized patient education and medical guidelines. While the original Assembly version focused on mandating physician disclosures, Senate amendments shifted the focus toward a collaborative "consensus conference" to establish statewide medical protocols.

Key Legislative Provisions & Medical Context

• Evolution of the Bill: The original Assembly version required attending physicians to inform pregnant patients about GBS early enough to allow for preventive action. The final Senate version instead required the Department of Health Services (DHS) to convene a "consensus conference" during the 1994-95 fiscal year.

• Collaborative Strategy: The conference was mandated to include representatives from major medical bodies, such as the American Academy of Pediatrics, the American College of Obstetricians and Gynecologists, and the Group B Strep Association.

• Standardized Information: Based on the conference, the DHS was tasked with developing a standardized written summary of GBS and prevention guidelines by July 1, 1995.

• Medical Significance of GBS: GBS is identified as the most common cause of pneumonia, meningitis, and blood infections in newborns. It typically causes illness within the first seven days of life but can affect infants up to three months of age.

• Comparison to Other Screenings: The bill's sponsor, the Group B Strep Association, noted that GBS poses a health risk as serious as rubella or spina bifida—conditions for which pregnant women are already routinely screened.

• Accountability: Under the initial proposal, a physician's failure to provide the required GBS information would have constituted unprofessional conduct, though it was not classified as a misdemeanor.

The following medical guidelines and legislative actions were a direct result of the consensus conference convened by the California Department of Health Services. This collaborative meeting included representatives from the American Academy of Pediatrics, the American College of Obstetricians and Gynecologists, and the Group B Strep Association to establish standardized prevention protocols.

Prevention of Perinatal Group B Streptococcal Disease (CDC MMWR)

This 1996 CDC report establishes the epidemiologic basis and public health guidelines for preventing neonatal Group B streptococcal (GBS) disease. As the leading bacterial infection associated with newborn illness and death in the U.S. since the 1970s, GBS causes severe conditions such as pneumonia, meningitis, and sepsis. The guidelines emphasize that most infections are preventable through intrapartum antimicrobial prophylaxis (IAP)—administering antibiotics to the mother during labor.

Key Facts & Clinical Recommendations

• Risk Factors: High-risk conditions include maternal GBS colonization, delivery at less than 37 weeks' gestation, fever during labor ($\ge 100.4^{\circ}$F), and prolonged rupture of membranes ($\ge 18$ hours).

• Prevention Strategies: The CDC recommends two equally acceptable approaches:

  • Screening-Based Approach: Routine rectovaginal GBS cultures for all pregnant women at 35–37 weeks' gestation, with IAP offered to all identified carriers.

  • Risk-Factor Approach: Providing IAP to any woman who develops specific clinical risk factors during labor, regardless of culture status.

• Preferred Treatment: Intravenous Penicillin G is the recommended first-line agent due to its narrow spectrum, which helps prevent the emergence of multi-drug resistant organisms. Ampicillin is an acceptable alternative.

• Neonatal Impact: Infants with GBS disease may require prolonged hospitalization, and survivors often suffer permanent disabilities, including hearing loss, vision loss, or mental retardation.

• Protocol for Newborns: The CDC provides an algorithm for managing neonates born to mothers who received IAP, focusing on clinical signs of sepsis, gestational age, and the duration of maternal antibiotic treatment before delivery.

• Screening Technique: Optimal GBS recovery requires swabs of both the vaginal introitus and anorectum, which must be processed using selective broth media (e.g., Lim or SBM broth).